RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer

In metastatic colorectal cancer, RAS and BRAF mutations cause resistance to anti‐EGFR therapies, such as cetuximab. Heterogeneity in RAS and BRAF mutations might explain nonresponse in a subset of patients receiving cetuximab. Analyzing mutations in plasma‐derived circulating tumor DNA (ctDNA) could...

Descripción completa

Detalles Bibliográficos
Autores principales: van Helden, Erik J., Angus, Lindsay, Menke‐van der Houven van Oordt, C. Willemien, Heideman, Daniëlle A. M., Boon, Eline, van Es, Suzanne C., Radema, Sandra A., van Herpen, Carla M. L., de Groot, Derk Jan A., de Vries, Elisabeth G. E., Jansen, Maurice P. H. M., Sleijfer, Stefan, Verheul, Henk M. W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822250/
https://www.ncbi.nlm.nih.gov/pubmed/31350822
http://dx.doi.org/10.1002/1878-0261.12550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822250/
https://www.ncbi.nlm.nih.gov/pubmed/31350822
http://dx.doi.org/10.1002/1878-0261.12550

Ejemplares similares